Full Press Release Details
Findings to be Presented During Poster Session at Kidney Week 2023
Poster Title: Small molecule inhibition of APOL1 reverses albuminuria in a chronic mouse model of APOL1-mediated renal disease Poster Board #: SA-PO788 Session Title: Genetic Diseases: Glomerulopathies – II [PO1202-3] Session Date, Time: November 4, 2023, from 10:00 a.m. to 12:00 p.m. ET
About Maze Therapeutics Maze Therapeutics is a biopharmaceutical company harnessing the power of human genetics to transform the lives of patients. The Company is committed to developing breakthrough precision medicines for common diseases with large unmet medical needs. Maze has developed Maze Compass™, a proprietary, purpose-built platform to leverage genetic variation and integrate the critical step of variant functionalization into each stage of therapeutic development. Utilizing Maze Compass, the Company’s strategy is to develop its therapies independently, in collaboration with major pharmaceutical companies, and through company formation. For more information, please visit mazetx.com, or follow us on LinkedIn and X . (formerly Twitter).